Morse Asset Management, Inc Clovis Oncology, Inc. Transaction History

Morse Asset Management, Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2018 Nov 01, 2018	SELL	$29.37 - $49.48 $393,558 - $663,032	-13,400 Closed	0 $0
Q2 2018 Aug 15, 2018	BUY	$42.06 - $62.4 $69,399 - $102,960	1,650 Added 14.04%	13,400 $609,000
Q1 2018 May 02, 2018	BUY	$50.12 - $67.72 $355,852 - $480,812	7,100 Added 152.69%	11,750 $620,000
Q4 2017 Jan 29, 2018	SELL	$57.69 - $84.58 $1.4 Million - $2.05 Million	-24,270 Reduced 83.92%	4,650 $316,000
Q3 2017 Oct 31, 2017	BUY	$67.17 - $84.81 $1.94 Million - $2.45 Million	28,920	28,920 $2.38 Million

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Morse Asset Management, Inc, based on Form 13F filings with the SEC.

Stay updated on Morse Asset Management, Inc with notifications on news.